Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chembio Clears Path For HIV Tests With Patent, Marketing Agreement

This article was originally published in The Gray Sheet

Executive Summary

Chembio settled its legal disputes and found a marketing partner for its recently approved rapid HIV tests in a three-party agreement announced Oct. 5

You may also be interested in...



Chembio Plans Dual Path Platform Tests For Syphilis, HIV

Chembio Diagnostics will submit a 510(k) to FDA in 2010 for its Dual Path Platform Syphilis Screen & Confirm test, according to the company

Chembio Plans Dual Path Platform Tests For Syphilis, HIV

Chembio Diagnostics will submit a 510(k) to FDA in 2010 for its Dual Path Platform Syphilis Screen & Confirm test, according to the company

Clearview rapid HIV test

Clearview Complete HIV 1/2 is the latest rapid HIV test to gain a waiver for use in physicians' offices and clinics under the Clinical Laboratory Improvements Amendments, announced Nov. 2. The test, which uses "barrel" technology developed by StatSure Diagnostic Systems to detect antibodies in blood, serum and plasma, is manufactured by Chembio and marketed and distributed worldwide by Inverness Medical Innovations. Other CLIA-waived rapid HIV tests include OraSure's OraQuick Advance, Trinity's Uni-Gold Recombigen and Chembio's HIV 1/2 Stat-Pak (1"The Gray Sheet" Oct. 9, 2006, p. 16).

Related Content

UsernamePublicRestriction

Register

MT024057

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel